Esophageal Cancer Awareness Month: Expanding Treatment Options and Exploring New Directions With Harry Yoon, MD
Expert Perspectives · Keira Smith · 2025-04-02
April marks Esophageal Cancer Awareness Month, a time to shed light on one of the most aggressive cancers worldwide. The latest FDA approval for this disease, tislelizumab, was approved in March as first-line treatment for unresectable or metastatic esophageal squamous cell carcinoma (ESCC), based on the RATIONALE-306 trial (NCT03783442). The approval of tislelizumab marks a step forward in expanding first-line options for patients with advanced disease. Harry Yoon, MD, a Professor of Oncology at the Mayo Clinic and lead investigator of the RATIONALE-306 trial, sat down with Oncology Data Advisor to share his insights on the approval, the future of research in esophageal cancers, and messages for raising awareness in honor of Esophageal Cancer Awareness Month.
Click the button to subscribe to our emails, including the Monthly Newsletter and more!
Understanding Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma is one of the most common and aggressive cancers globally. Dr. Yoon highlights the dire need for effective treatments, stating, “Median survival has been only about a year in patients with stage IV disease, which is a large portion of this population. It’s clearly an area of unmet need.”
The RATIONALE-306 Trial and Tislelizumab
Tislelizumab, a programmed cell death protein 1 (PD-1) inhibitor, was evaluated in the global, phase 3 RATIONALE 306 trial. The trial tested whether adding tislelizumab to standard chemotherapy could improve overall survival. The median survival was about 17 months in those receiving tislelizumab versus 10 months in those receiving placebo.
Notably, 15% of patients in the tislelizumab arm remained progression-free three years after treatment. “These were patients with metastatic or advanced esophageal squamous cell carcinoma,” Dr. Yoon underscored. “It’s a really remarkable outcome in patients with this type of disease.”
Tislelizumab was found to have a side effect profile similar to other PD-1/programmed death ligand 1 (PD-L1) inhibitors, with no new safety signals seen.
Implications of FDA Approval
The FDA approval of tislelizumab provides oncologists with another viable option for treating ESCC. Dr. Yoon notes, “It gives us another option for patients in the US, an option that’s at least as efficacious as the two other options available, pembrolizumab and nivolumab.” He emphasizes that tislelizumab is the only immunotherapy tested in combination with a taxane doublet, making it a unique choice for specific patient scenarios.
Future Directions in ESCC Treatment
Looking ahead, Dr. Yoon highlights several promising areas of research, including:
- Targeting adaptive immunity with immune checkpoints
- Enhancing the delivery of cytotoxic agents through antibody-drug conjugates (ADCs)
- Combining angiogenesis inhibitors with PD-1 blockade
Raising Awareness During Esophageal Cancer Awareness Month
Dr. Yoon emphasizes the importance of raising awareness about the high death burden of esophageal cancer, which is the sixth most common cause of cancer-related deaths globally. He concludes, “Even with these immunotherapy advances, most patients still progress at some point or have to stop therapy due to toxicity. Continued public support for research is key to building on these advances.”
Key Takeaways
- Tislelizumab offers a new, effective option for first-line treatment of metastatic ESCC
- The RATIONALE-306 trial demonstrated significant survival benefits with tislelizumab
- Continued research and public support are essential to further improve outcomes for esophageal cancer patients
About Dr. Yoon
Harry Yoon, MD, is a Professor of Oncology at the Mayo Clinic and an internationally recognized expert in gastroesophageal cancers. His research focuses on developing novel genomic and molecularly informed therapies tailored to patients’ individual tumor and host environments. Dr. Yoon has led numerous phase 1 to 3 clinical trials investigating novel immunotherapies for gastroesophageal cancers.